Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Robert Hermann¹ · Mats O. Karlsson² · Ana M. Novakovic³ · Nadia Terranova⁴ · Markus Fluck³ · Alain Munafo⁴

Published online: 1 August 2018
© Springer Nature Switzerland AG 2018

Correction to: Clinical Pharmacokinetics
<https://doi.org/10.1007/s40262-018-0695-9>

Section 1, para 2, lines 2-4 which previously read:

The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), by deoxycytidine kinase.

Should read:

The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), primarily by deoxycytidine kinase.

Section 2.4, para 3, lines 4-6 which previously read:

Cd-AMP is further phosphorylated to chlorodeoxyadenosine diphosphate (Cd-ADP), and Cd-ADP is in turn phosphorylated by 5'-nucleotidase to Cd-ATP [10, 11].

Should read:

Cd-AMP is further phosphorylated to chlorodeoxyadenosine diphosphate (Cd-ADP), and Cd-ADP is in turn phosphorylated to Cd-ATP [10, 11].

The original article can be found online at <https://doi.org/10.1007/s40262-018-0695-9>.

✉ Robert Hermann
robert.hermann@cr-appliance.com

¹ Clinical Research Appliance (Cr Appliance),
Heinrich-Vingerhut-Weg 3, 63571 Gelnhausen, Germany

² Department of Pharmaceutical Biosciences, Uppsala
University, Uppsala, Sweden

³ Merck KGaA, Darmstadt, Germany

⁴ Merck Institute for Pharmacometrics, Merck Serono S.A.,
Switzerland, an Affiliate of Merck KGaA, Darmstadt,
Germany